Penthrox Regulatory Dossier accepted for review in Canada
15 June 2017
ASX ANNOUNCEMENT
Penthrox Regulatory Dossier accepted for review in Canada
Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox® submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada.
Accepting the MVP dossier for review, triggers a milestone payment of CAD$0.25 million from MVP’s partner, Purdue Pharma (Canada).
MVP Chief Executive Officer, Mr. John Sharman said: “This is another positive step towards globalizing Penthrox.”